-$0.04 Earnings Per Share Expected for Marrone Bio Innovations (MBII) This Quarter

Analysts expect Marrone Bio Innovations (NASDAQ:MBII) to announce ($0.04) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Marrone Bio Innovations’ earnings. Marrone Bio Innovations posted earnings of ($0.31) per share in the same quarter last year, which suggests a positive year over year growth rate of 87.1%. The company is scheduled to report its next earnings report on Thursday, May 10th.

On average, analysts expect that Marrone Bio Innovations will report full year earnings of ($0.14) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.12) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Marrone Bio Innovations.

Marrone Bio Innovations (NASDAQ:MBII) last announced its quarterly earnings data on Thursday, March 29th. The basic materials company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.02. The business had revenue of $3.32 million during the quarter.

Several research firms have recently weighed in on MBII. HC Wainwright set a $4.00 target price on shares of Marrone Bio Innovations and gave the stock a “buy” rating in a research report on Thursday, December 21st. Jefferies Group reissued a “hold” rating and issued a $1.55 target price on shares of Marrone Bio Innovations in a research report on Wednesday, March 21st. ValuEngine downgraded shares of Marrone Bio Innovations from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Zacks Investment Research downgraded shares of Marrone Bio Innovations from a “hold” rating to a “sell” rating in a research report on Thursday, February 15th. Finally, BidaskClub downgraded shares of Marrone Bio Innovations from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 12th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $2.18.

Shares of MBII traded up $0.02 during mid-day trading on Wednesday, hitting $1.85. The company’s stock had a trading volume of 3,273,863 shares, compared to its average volume of 347,297. The stock has a market capitalization of $199.08, a P/E ratio of -1.73 and a beta of -0.54. The company has a debt-to-equity ratio of -1.23, a current ratio of 0.87 and a quick ratio of 0.42. Marrone Bio Innovations has a fifty-two week low of $0.85 and a fifty-two week high of $3.39.

In other news, insider Ardsley Advisory Partners bought 6,666,667 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were acquired at an average cost of $0.75 per share, with a total value of $5,000,000.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Week Herald and is owned by of Week Herald. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://weekherald.com/2018/04/25/0-04-earnings-per-share-expected-for-marrone-bio-innovations-mbii-this-quarter.html.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.

Get a free copy of the Zacks research report on Marrone Bio Innovations (MBII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply